# Viking Global Investors

> Viking Global Investors is a VC fund backing Biotechnology and Health Care. See 195 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Greenwich, United States
- Total investments: 195
- Last investment: Jul 2026
- Lead investor: 37%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/viking-global-investors
- Website: https://www.vikingglobal.com/

Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies.The firm was established in 1999 and is headquartered in Greenwich, Connecticut, withoffices in New York City, Hong Kong, and London.

## Contacts

5 contacts available for Viking Global Investors. Shizune tracks 3 team members at Viking Global Investors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/viking-global-investors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 75 | 38% |
| Health Care | 50 | 26% |
| Therapeutics | 33 | 17% |
| Medical | 30 | 15% |
| Pharmaceutical | 24 | 12% |

120 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 37 | 19% |
| Series C | 27 | 14% |
| Series A | 25 | 13% |
| Series D | 16 | 8% |
| Series E | 13 | 7% |

16 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 104 | 53% |
| Canada | 5 | 3% |
| United Kingdom | 4 | 2% |
| China | 2 | 1% |
| Brazil | 1 | 1% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Karim Helmy | Private Investments | 1 | https://shizune.co/investors/profile/karim-helmy |
| Ellis Whipple | CFO | 0 | https://shizune.co/investors/profile/ellis-whipple-5485 |
| Ole Andreas Halvorsen | Founder | 0 | https://shizune.co/investors/profile/ole-andreas-halvorsen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pearl Health | Pearl Health’s mission is to democratize access to value in healthcare.Pearl empowers primary care physicians to deliver better quality care for their patients at a lower cost via a physician enablement technology platform and a value-based payment model.Pearl’s technology provides visibility into patient panel health, simple financialreporting, and recommendations to deliver care to patients who need it most.To date, we have raised more than $20m from investors including Andreessen Horowitz and AlleyCorp, and we’re working with 300+ physicians and 20,000+ lives in value-based models. | $50M | Series C | Jul 08, 2026 |  |
| GT Medical Technologies | GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M | Series E | Jun 09, 2026 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |
| AlphaSense | AlphaSense is a market intelligence platform that allows professionals to make critical decisions with confidence and speed. The company has nearly 2,000 enterprise clients, including financial institutions that use the platform to inform their business decisions. AlphaSense is trusted by over 1,800 enterprise customers, including a majority of theS&P 500. | $350M | Venture - Series Unknown | Jun 03, 2026 |  |
| Artiva Biotherapeutics | Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M | Post-IPO Equity | May 08, 2026 |  |
| Altimmune | Altimmune is an emerging biotechnology company located in Montgomery County, MD. Altimmune develops vaccines and other biological products to address unmet market and public health needs. The company uses a proprietary technology for non-invasive intranasal delivery, and has shown proof of principle in animals and in initial human clinical studies.Vaxin Inc., formerly known as Vaxin Pharmaceuticals and ImmuneFocus Corporation, was founded in 1997 by Emerging Technology Partners. Early experiments revealed that DNA incorporated into an adenovirus can elicit an immune response when placed on the surface of the skin, and subsequently research was expanded to include applications on the skin in the nose as well as experimentation with other vectors. | $225M | Post-IPO Equity | Apr 22, 2026 |  |
| Valstone | Valstone is a global provider of software and technology solutions for the industrial sector. |  | Private Equity | Mar 09, 2026 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M |  | Mar 02, 2026 |  |
| Diagonal Therapeutics | Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M | Series B | Jan 08, 2026 |  |
| Allonnia | Allonnia is a bioremediation company focused on waste management. | $20M | Series A | Dec 10, 2025 |  |

10 of 195 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 22 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 22 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 16 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 15 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 14 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 14 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Viking Global Investors invest in?

Viking Global Investors invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 195 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Viking Global Investors?

Public channels for Viking Global Investors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Viking Global Investors?

The team at Viking Global Investors includes Karim Helmy (Private Investments), Ellis Whipple (CFO) and Ole Andreas Halvorsen (Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co